Prophylactic pegfilgrastim support with adjuvant docetaxel, doxorubicin and cyclophosphamide (TAC) in node-positive breast cancer patients

被引：0
|
作者：
Rifa, Juli [1 ]
Del Alba, A. Gonzalez [1 ]
Perello, A. [1 ]
Alarcon, J. [1 ]
Avella, A. [1 ]
机构：
[1] Hosp Son Dureta, Palma De Mallorca, Spain
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：112 / 112
页数：1
相关论文
共 50 条
  • [1] Weight gain after adjuvant TAC (docetaxel, doxorubicin, and cyclophosphamide) chemotherapy for node-positive breast cancer
    Suh, Y.
    Oh, S.
    Song, B.
    Jung, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects
    Au, Heather-Jane
    Golmohammadi, Kamran
    Younis, Tallal
    Verma, Shailendra
    Chia, Stephen
    Fassbender, Konrad
    Jacobs, Philip
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (03) : 579 - 587
  • [3] Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects
    Heather-Jane Au
    Kamran Golmohammadi
    Tallal Younis
    Shailendra Verma
    Stephen Chia
    Konrad Fassbender
    Philip Jacobs
    [J]. Breast Cancer Research and Treatment, 2009, 114 : 579 - 587
  • [4] TAC (docetaxel, doxorubicin, and cyclophosphamide) adjuvant chemotherapy supported by G-CSF without dose-reduction in node-positive breast cancer
    Suh, Y.
    Oh, S.
    Song, B.
    Jung, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Weight change and its impact on prognosis after adjuvant TAC (docetaxel–doxorubicin–cyclophosphamide) chemotherapy in Korean women with node-positive breast cancer
    Ye Won Jeon
    Seung Taek Lim
    Hyun Joo Choi
    Young Jin Suh
    [J]. Medical Oncology, 2014, 31
  • [6] Adjuvant docetaxel for node-positive breast cancer
    Noronha, V
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (09): : 954 - 954
  • [7] Adjuvant docetaxel for node-positive breast cancer
    Martin, M
    Pienkowski, T
    Mackey, J
    Pawlicki, M
    Guastalla, JP
    Weaver, C
    Tomiak, E
    Al-Tweigeri, T
    Chap, L
    Juhos, E
    Guevin, R
    Howell, A
    Fornander, T
    Hainsworth, J
    Coleman, R
    Vinholes, J
    Modiano, M
    Pinter, T
    Tang, SC
    Colwell, B
    Prady, C
    Provencher, L
    Walde, D
    Rodriguez-Lescure, A
    Hugh, J
    Loret, C
    Rupin, M
    Blitz, S
    Jacobs, P
    Murawsky, M
    Riva, A
    Vogel, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (22): : 2302 - 2313
  • [8] Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy
    Jeon, Ye Won
    Lim, Seung Taek
    Gwak, HongKi
    Park, Seon Young
    Suh, Young Jin
    [J]. JOURNAL OF BREAST CANCER, 2020, 23 (05) : 521 - 532
  • [9] Weight change and its impact on prognosis after adjuvant TAC (docetaxel-doxorubicin-cyclophosphamide) chemotherapy in Korean women with node-positive breast cancer
    Jeon, Ye Won
    Lim, Seung Taek
    Choi, Hyun Joo
    Suh, Young Jin
    [J]. MEDICAL ONCOLOGY, 2014, 31 (03)
  • [10] Adjuvant docetaxel plus doxorubicin and cyclophosphamide increases survival compared with fluorouracil plus doxorubicin and cyclophosphamide in women with operable node-positive breast cancer
    Roy, V
    Perez, EA
    [J]. CANCER TREATMENT REVIEWS, 2006, 32 (01) : 55 - 58
12345